# I Tried a GLP-1 Experiment. The Numbers Say It Worked.
GLP-1 receptor agonists, the class of medications that includes Ozempic, Wegovy, and Mounjaro, dominate health conversations right now. A Men's Health journalist decided to test what these drugs actually deliver by using one himself and tracking the results.
The experiment revealed a central tension in how we measure health success. The biomarkers improved dramatically. Weight dropped. Blood sugar metrics shifted into healthier ranges. Cholesterol numbers moved in favorable directions. Every clinical marker that doctors use to assess metabolic health showed measurable improvement.
Yet something else emerged from the data: the person taking the medication felt largely unchanged. The internal experience didn't match the external results.
This disconnect matters for parents watching the GLP-1 conversation unfold. These medications work at a biochemical level. They slow gastric emptying, which means food moves through your system more slowly. They reduce appetite by acting on brain regions that control hunger. They improve how your body processes glucose. The science is solid. Pharmaceutical companies like Eli Lilly, Novo Nordisk, and Roche have invested billions in developing and marketing these drugs.
But biology and lived experience operate on different timelines and in different languages.
The journalist's experiment touches on something parents need to understand as these medications trickle into younger populations. We have excellent data on what GLP-1s do to your body. Pediatric trials continue, and the FDA approved Wegovy for teens ages 12 and up in 2023. The efficacy numbers look strong, particularly for young people with obesity and related metabolic complications.
What we have less data on is the psychological and behavioral impact of taking these medications long-term, especially during adolescence. Does improving biomarkers create sustainable health habits, or does it defer the work of building them? What happens to someone's relationship with food and exercise when a medication does the work for them? The blood work won't answer those questions.
The Men's Health experiment also highlights the placebo problem. Humans expect to feel different when something changes their body. When the numbers improve but subjective experience stalls, it creates cognitive dissonance. That matters in medication compliance. People stick with treatments that feel like they're working, not just treatments that produce numbers.
Parents considering GLP-1s for their children should view these medications as tools, not solutions. They're most effective when combined with nutritional counseling, increased physical activity, and behavioral change work. The medications create a window of opportunity. Whether families use that window to build lasting habits determines whether the benefits stick after medication ends.
The data from this journalist's experiment demonstrates that GLP-1s deliver what they promise on a metabolic level. The clinical improvements are real. What remains unclear is whether metabolic improvements alone create the foundation for lasting health change. That answer depends less on the medication and more on what families do with the opportunity it creates.